Přejete si pokračovat a opustit stránky a opustit Amgen.cz?

NYNÍ OPOUŠTÍTE WEBOVÉ STRÁNKY SPOLEČNOSTI AMGEN. Naše společnost nepřebírá žádnou odpovědnost za obsah následujících webových stránek a ani nijak nekontroluje přesnost informací na nich uvedených.


Jste odborný pracovník ve zdravotnictví?

Jsem odborníkem ve smyslu §2a Zákona č. 40/1995 Sb., o regulaci reklamy, ve znění pozdějších předpisů, čili jsem osobou oprávněnou předepisovat léčivé přípravky nebo osobou vydávat léčivé léky.

Potvrzuji, že jsem se seznámil/a s definicí odborník dle zákona č. 40/1995 Sb.
Potvrzuji, že jsem se seznámil/a s riziky, jímž se jiná osoba než odborník vystavuje, vstoupá-li na stránky určené pro odborníky

Amgen Update Regarding COVID-19 For Media

March 23, 2020

As the COVID-19 pandemic continues to evolve, we are committed to doing everything we can to keep our staff and their families safe, as well as to help the communities where we live and work reduce the number of people exposed to the virus. We are also committed to continuing to deliver an uninterrupted supply of our medicines for the patients who need them.

Staff and Community

  • Effective Monday, March 16, we are encouraging any staff member who is able to work from home to do so until further notice. This includes staff at our corporate headquarters in Thousand Oaks, CA. Our teams in Asia have been proactively modeling this behavior for many weeks and in some cases are now returning to work based on local conditions and guidance from local health officials.
  • In addition, we have made the decision to suspend all in-person meetings and interactions with the healthcare community and professionals in the U.S. until April 17. As of March 16, all U.S. field staff will work from home and move to a virtual interaction model.
  • Amgen has suspended international business travel and limited domestic travel within the U.S. through April 17.
  • We have suspended attendance at medical congresses, conferences and other large events through April 17.
  • Enhanced cleaning procedures and visitor screening are being implemented at all Amgen locations.
  • Amgen and the Amgen Foundation have committed up to $12.5 million to support COVID-19 relief efforts. The funds will be used to support emergency response efforts in Amgen’s U.S. and international communities, patient-focused organizations that are mounting their own response efforts, and international relief efforts by Direct Relief and International Medical Corps. The Amgen Foundation will also match donations made by Amgen staff around the globe who wish to contribute their own funds to the relief efforts
  • Free online learning programs supported by the Amgen Foundation are available to help students continue their science education during school closures.

Supply of Our Medicines

  • Amgen continues to provide an uninterrupted supply of medicines for patients around the world. Based on inventory levels, we do not anticipate a shortage of our medicines due to COVID-19 at this time.
  • We are monitoring our raw material inventory levels and taking additional measures to mitigate against interruption.

Clinical Trials and R&D Efforts

  • We have a vast amount of clinical work going on at investigational sites across the globe. We are monitoring this dynamic situation closely.

Impact to Our Business

  • We activated our business continuity plans to avoid or minimize business disruption and ensure the well-being of our staff.
  • We don’t know the extent to which COVID-19 (coronavirus) will continue to spread and impact society.
  • At this stage, we cannot rule out future impact on our business including sales, manufacturing and clinical trials.